1. Centers for Disease Control and Prevention . Chronic kidney disease surveillance system. Accessed August 16, 2021. https://nccd.cdc.gov/CKD.
Google Scholar2. Eknoyan, G, Lameire, N, Eckardt, KU, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1)(suppl):1–150. doi:10.1038/kisup.2012.74.
Google Scholar | Crossref3. Go, AS, Chertow, GM, Fan, D, McCulloch, CE, Hsu, CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. doi:10.1056/NEJMoa041031.
Google Scholar | Crossref | Medline | ISI4. Ronco, P, Rovin, B, Schlondorff, D, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1–S115. doi:10.1016/j.kint.2020.06.019.
Google Scholar | Crossref | Medline5. Kolkhof, P, Jaisser, F, Kim, SY, Filippatos, G, Nowack, C, Pitt, B. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. Handb Exp Pharmacol. 2017;243:271–305. doi:10.1007/164_2016_76.
Google Scholar | Crossref | Medline6. Agarwal, R, Kolkhof, P, Bakris, G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152–161. doi:10.1093/eurheartj/ehaa736.
Google Scholar | Crossref | Medline7. Pfizer. Aldactone (spironolactone) . New York, NY; 2021. Accessed December 13, 2021. https://www.pfizer.com/products/product-detail/aldactone.
Google Scholar8. Pfizer. Inspra (eplerenone) . New York, NY; 2016. Accessed December 13, 2021. https://www.pfizer.com/products/product-detail/inspra.
Google Scholar | Crossref9. Bayer HealthCare Pharmaceuticals, Inc . Kerendia (finerenone). Whippany, NJ; 2021. Accessed December 13, 2021. https://www.kerendiahcp.com/.
Google Scholar10. Kolkhof, P, Delbeck, M, Kretschmer, A, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69–78. doi:10.1097/FJC.0000000000000091.
Google Scholar | Crossref | Medline11. Barrera-Chimal, J, Estrela, GR, Lechner, SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018;93(6):1344–1355. doi:10.1016/j.kint.2017.12.016.
Google Scholar | Crossref | Medline12. Pitt, B, Kober, L, Ponikowski, P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–2463. doi:10.1093/eurheartj/eht187.
Google Scholar | Crossref | Medline13. Filippatos, G, Anker, SD, Bohm, M, et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 2016;37(27):2105–2114. doi:10.1093/eurheartj/ehw132.
Google Scholar | Crossref | Medline14. Bakris, GL, Agarwal, R, Chan, JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894. doi:10.1001/jama.2015.10081.
Google Scholar | Crossref | Medline15. Bakris, GL, Agarwal, R, Anker, SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229. doi:10.1056/NEJMoa2025845.
Google Scholar | Crossref | Medline16. Pitt, B, Filippatos, G, Agarwal, R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–2263. doi:10.1056/NEJMoa2110956.
Google Scholar | Crossref | Medline17. Bakris, GL, Agarwal, R, Anker, SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333–344. doi:10.1159/000503713.
Google Scholar | Crossref | Medline18. Filippatos, G, Anker, SD, Agarwal, R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation. 2021;143(6):540–552. doi:10.1161/CIRCULATIONAHA.120.051898.
Google Scholar | Crossref | Medline19. Ruilope, LM, Agarwal, R, Anker, SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):345–356. doi:10.1159/000503712.
Google Scholar | Crossref | Medline20. Antipolis, S . Finerenone benefits patients with diabetes across spectrum of kidney disease. European Society of Cardiology; 2021. Accessed September 27, 2021. https://www.escardio.org/The-ESC/Press-Office/Press-releases/Finerenone-benefits-patients-with-diabetes-across-spectrum-of-kidney-disease.
Google Scholar21. ClinicalTrials.gov . Study to evaluate the efficacy (effect on disease) and safety of finerenone on morbidity (events indicating disease worsening) & mortality (death rate) in participants with heart failure and left ventricular ejection fraction (proportion of blood expelled per heart stroke) greater or equal to 40% (FINEARTS-HF). Accessed August 31, 2021. https://clinicaltrials.gov/ct2/show/NCT04435626.
Google Scholar